Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer

Susan K. Quella, Charles Lawrence Loprinzi, Jeff A Sloan, Paul Novotny, Edith A. Perez, Patrick A. Burch, Stanley J. Antolak, Thomas M. Pisansky

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Purpose: Hot flashes may be a significant clinical problem in men undergoing androgen deprivation therapy with gonadotropin releasing hormone analogues, oral antiandrogens and/or surgical bilateral orchiectomy. Anecdotal information suggests that a low dose of the relatively new antidepressant venlafaxine may abrogate this clinical problem. We developed the current pilot trial to investigate further whether venlafaxine alleviates hot flashes in such men. Materials and Methods: The study included men in whom substantial hot flashes were associated with androgen deprivation therapy. Hot flash data were collected by daily diary questionnaires during a 1-week baseline period when no therapy was given for hot flashes, as well as for the next 4 weeks when study participants received 12.5 mg. venlafaxine orally twice daily. Questionnaires completed during the 4 weeks of venlafaxine therapy also documented data on potential drug toxicity. Results: Of the 16 evaluable patients who completed the study 10 (63%) had a greater than 50% decrease in hot flash score, as determined using the formula, frequency x severity, by week 4 of treatment versus the baseline week. Median weekly hot flash scores decreased 54% from baseline during week 4 of venlafaxine therapy. Average incidence of severe and very severe hot flashes was reduced from 2.3 daily at baseline to 0.6 daily at study end (p = 0.003). Therapy was generally well tolerated. Conclusions: Venlafaxine hydrochloride appears to represent an efficacious new method for alleviating hot flashes in men undergoing androgen ablation therapy. Further evaluation of t his compound for alleviating hot flashes is indicated.

Original languageEnglish (US)
Pages (from-to)98-102
Number of pages5
JournalJournal of Urology
Volume162
Issue number1
DOIs
StatePublished - Jul 1999

Fingerprint

Hot Flashes
Androgens
Prostatic Neoplasms
Therapeutics
Venlafaxine Hydrochloride
Androgen Antagonists
Orchiectomy
Drug-Related Side Effects and Adverse Reactions
Gonadotropin-Releasing Hormone
Antidepressive Agents

Keywords

  • Hot flashes
  • Prostate
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. / Quella, Susan K.; Loprinzi, Charles Lawrence; Sloan, Jeff A; Novotny, Paul; Perez, Edith A.; Burch, Patrick A.; Antolak, Stanley J.; Pisansky, Thomas M.

In: Journal of Urology, Vol. 162, No. 1, 07.1999, p. 98-102.

Research output: Contribution to journalArticle

Quella, Susan K. ; Loprinzi, Charles Lawrence ; Sloan, Jeff A ; Novotny, Paul ; Perez, Edith A. ; Burch, Patrick A. ; Antolak, Stanley J. ; Pisansky, Thomas M. / Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. In: Journal of Urology. 1999 ; Vol. 162, No. 1. pp. 98-102.
@article{6f3dcaced4474ada9ad11f3bed155043,
title = "Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer",
abstract = "Purpose: Hot flashes may be a significant clinical problem in men undergoing androgen deprivation therapy with gonadotropin releasing hormone analogues, oral antiandrogens and/or surgical bilateral orchiectomy. Anecdotal information suggests that a low dose of the relatively new antidepressant venlafaxine may abrogate this clinical problem. We developed the current pilot trial to investigate further whether venlafaxine alleviates hot flashes in such men. Materials and Methods: The study included men in whom substantial hot flashes were associated with androgen deprivation therapy. Hot flash data were collected by daily diary questionnaires during a 1-week baseline period when no therapy was given for hot flashes, as well as for the next 4 weeks when study participants received 12.5 mg. venlafaxine orally twice daily. Questionnaires completed during the 4 weeks of venlafaxine therapy also documented data on potential drug toxicity. Results: Of the 16 evaluable patients who completed the study 10 (63{\%}) had a greater than 50{\%} decrease in hot flash score, as determined using the formula, frequency x severity, by week 4 of treatment versus the baseline week. Median weekly hot flash scores decreased 54{\%} from baseline during week 4 of venlafaxine therapy. Average incidence of severe and very severe hot flashes was reduced from 2.3 daily at baseline to 0.6 daily at study end (p = 0.003). Therapy was generally well tolerated. Conclusions: Venlafaxine hydrochloride appears to represent an efficacious new method for alleviating hot flashes in men undergoing androgen ablation therapy. Further evaluation of t his compound for alleviating hot flashes is indicated.",
keywords = "Hot flashes, Prostate, Prostatic neoplasms",
author = "Quella, {Susan K.} and Loprinzi, {Charles Lawrence} and Sloan, {Jeff A} and Paul Novotny and Perez, {Edith A.} and Burch, {Patrick A.} and Antolak, {Stanley J.} and Pisansky, {Thomas M.}",
year = "1999",
month = "7",
doi = "10.1097/00005392-199907000-00024",
language = "English (US)",
volume = "162",
pages = "98--102",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer

AU - Quella, Susan K.

AU - Loprinzi, Charles Lawrence

AU - Sloan, Jeff A

AU - Novotny, Paul

AU - Perez, Edith A.

AU - Burch, Patrick A.

AU - Antolak, Stanley J.

AU - Pisansky, Thomas M.

PY - 1999/7

Y1 - 1999/7

N2 - Purpose: Hot flashes may be a significant clinical problem in men undergoing androgen deprivation therapy with gonadotropin releasing hormone analogues, oral antiandrogens and/or surgical bilateral orchiectomy. Anecdotal information suggests that a low dose of the relatively new antidepressant venlafaxine may abrogate this clinical problem. We developed the current pilot trial to investigate further whether venlafaxine alleviates hot flashes in such men. Materials and Methods: The study included men in whom substantial hot flashes were associated with androgen deprivation therapy. Hot flash data were collected by daily diary questionnaires during a 1-week baseline period when no therapy was given for hot flashes, as well as for the next 4 weeks when study participants received 12.5 mg. venlafaxine orally twice daily. Questionnaires completed during the 4 weeks of venlafaxine therapy also documented data on potential drug toxicity. Results: Of the 16 evaluable patients who completed the study 10 (63%) had a greater than 50% decrease in hot flash score, as determined using the formula, frequency x severity, by week 4 of treatment versus the baseline week. Median weekly hot flash scores decreased 54% from baseline during week 4 of venlafaxine therapy. Average incidence of severe and very severe hot flashes was reduced from 2.3 daily at baseline to 0.6 daily at study end (p = 0.003). Therapy was generally well tolerated. Conclusions: Venlafaxine hydrochloride appears to represent an efficacious new method for alleviating hot flashes in men undergoing androgen ablation therapy. Further evaluation of t his compound for alleviating hot flashes is indicated.

AB - Purpose: Hot flashes may be a significant clinical problem in men undergoing androgen deprivation therapy with gonadotropin releasing hormone analogues, oral antiandrogens and/or surgical bilateral orchiectomy. Anecdotal information suggests that a low dose of the relatively new antidepressant venlafaxine may abrogate this clinical problem. We developed the current pilot trial to investigate further whether venlafaxine alleviates hot flashes in such men. Materials and Methods: The study included men in whom substantial hot flashes were associated with androgen deprivation therapy. Hot flash data were collected by daily diary questionnaires during a 1-week baseline period when no therapy was given for hot flashes, as well as for the next 4 weeks when study participants received 12.5 mg. venlafaxine orally twice daily. Questionnaires completed during the 4 weeks of venlafaxine therapy also documented data on potential drug toxicity. Results: Of the 16 evaluable patients who completed the study 10 (63%) had a greater than 50% decrease in hot flash score, as determined using the formula, frequency x severity, by week 4 of treatment versus the baseline week. Median weekly hot flash scores decreased 54% from baseline during week 4 of venlafaxine therapy. Average incidence of severe and very severe hot flashes was reduced from 2.3 daily at baseline to 0.6 daily at study end (p = 0.003). Therapy was generally well tolerated. Conclusions: Venlafaxine hydrochloride appears to represent an efficacious new method for alleviating hot flashes in men undergoing androgen ablation therapy. Further evaluation of t his compound for alleviating hot flashes is indicated.

KW - Hot flashes

KW - Prostate

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0032861507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032861507&partnerID=8YFLogxK

U2 - 10.1097/00005392-199907000-00024

DO - 10.1097/00005392-199907000-00024

M3 - Article

C2 - 10379749

AN - SCOPUS:0032861507

VL - 162

SP - 98

EP - 102

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -